©2022 Stanford Medicine
PET/MRI in the Diagnosis of Chronic Pain
Recruiting
I'm InterestedTrial ID: NCT03556137
Purpose
Several studies have implicated involvement of sigma-1 receptors (SR1s) in the generation of
chronic pain, while others are investigating anti SR1 drugs for treatment of chronic pain.
Using [18F]-FTC-146 and positron emission tomography/magnetic resonance imaging (PET/MRI),
the investigators hope to identify the source of pain generation in patients with chronic
pain. The purpose of this study is to compare the uptake of [18F]FTC-146 in healthy
volunteers to that of individuals suffering from chronic pain.
Official Title
Use of [18F]FTC-146 PET/MRI in the Diagnosis of Chronic Pain
Stanford Investigator(s)
Anand Veeravagu
Associate Professor of Neurosurgery and, by courtesy, of Orthopaedic Surgery
Sandip Biswal, MD
Adjunct Clinical Professor, Radiology
Eligibility
Inclusion Criteria:
Healthy Volunteers:
1. At least 18 years old.
2. Covid Vaccination status: Vaccinated or unvaccinated subjects who received a negative
test result from the Covid test within 72 hours of the scan.
Pain Patients:
1. At least 18 years old.
2. Chronic pain (nociceptive, neuropathic or mixed pain) lasting greater than 2 months.
3. Pain level of at least 4/10 on a 0-10 Comparative Pain Scale.
4. Covid Vaccination status: Vaccinated or unvaccinated subjects who received a negative
test result from the Covid test within 72 hours of the scan.
Exclusion Criteria:
Healthy Volunteers:
1. Pain
2. Pain Medication
3. MRI incompatible
4. Pregnant or nursing
5. Non-English speaker
6. Claustrophobic
Pain Patients:
1. MRI incompatible
2. Pregnant or nursing
3. Non-English speaker
4. Claustrophobic
Intervention(s):
drug: [18F]FTC-146
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Adrian Valladarez, BA